BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34558296)

  • 21. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
    Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
    Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
    Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
    O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
    Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer.
    Chen WY; Wu CT; Wang CW; Lan KH; Liang HK; Huang BS; Chang YL; Kuo SH; Cheng AL
    Radiat Oncol; 2018 Aug; 13(1):157. PubMed ID: 30153850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
    Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
    J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+ Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer.
    Lee J; Jung YY; Lee JH; Hong M; Hwang HW; Hong SA; Hong SH
    Oncology; 2021; 99(8):528-538. PubMed ID: 34107469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy.
    Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Takada Y; Hori M; Miura K; Kitagawa M; Gocho T; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Sakata KI
    Jpn J Clin Oncol; 2020 Oct; 50(11):1290-1297. PubMed ID: 33089868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
    Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
    Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
    Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.
    Kadota K; Yeh YC; Villena-Vargas J; Cherkassky L; Drill EN; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Chest; 2015 Sep; 148(3):711-721. PubMed ID: 25836013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.